NASDAQ:SOPH • CH1125843347
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SOPHIA GENETICS SA (SOPH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-26 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-10 | BTIG | Maintains | Buy -> Buy |
| 2024-12-18 | Craig-Hallum | Initiate | Buy |
| 2024-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-27 | Guggenheim | Initiate | Buy |
| 2024-03-06 | BTIG | Maintains | Buy -> Buy |
| 2024-03-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-01-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-11-29 | RBC Capital | Initiate | Outperform |
| 2023-05-10 | Credit Suisse | Maintains | Neutral |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-03-08 | Morgan Stanley | Maintains | Overweight |
| 2023-01-03 | BTIG | Initiate | Buy |
| 2022-11-23 | Credit Suisse | Initiate | Neutral |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-05-11 | Morgan Stanley | Maintains | Overweight |
| 2022-02-15 | Morgan Stanley | Maintains | Overweight |
| 2021-08-17 | Cowen & Co. | Initiate | Outperform |
| 2021-08-17 | JP Morgan | Initiate | Overweight |
| 2021-08-17 | Credit Suisse | Initiate | Outperform |
| 2021-08-17 | Morgan Stanley | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 62.371M 31.14% | 65.173M 4.49% | 77.271M 18.56% | 89.76M 16.16% | 105.52M 17.56% | 132.04M 25.13% | 184.31M 39.59% | 238.99M 29.67% | |
| EBITDA YoY % growth | -66.49M 19.16% | -57.972M 12.81% | -58.052M -0.14% | -37.692M 35.07% | -26.806M 28.88% | -8.823M 67.09% | 24.786M 380.92% | 61.608M 148.56% | |
| EBIT YoY % growth | -74.826M 14.80% | -66.568M 11.04% | -67.581M -1.52% | -61.967M 8.31% | -52.229M 15.72% | -32.283M 38.19% | -5.712M 82.31% | 29.478M 616.07% | |
| Operating Margin | -119.97% | -102.14% | -87.46% | -69.04% | -49.50% | -24.45% | -3.10% | 12.33% | |
| EPS YoY % growth | -1.22 -4.27% | -0.95 22.13% | -1.12 -17.89% | -0.91 18.49% | -0.75 17.60% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.25 4.87% | -0.25 25.05% | -0.23 18.95% | -0.20 21.12% | -0.21 13.40% | -0.18 25.77% | -0.15 32.58% | -0.12 37.93% |
| Revenue Q2Q % growth | 20.808M 17.04% | 21.522M 17.46% | 22.925M 17.79% | 24.582M 13.24% | 22.746M 9.31% | 24.888M 15.64% | 26.52M 15.68% | 28.866M 17.43% |
| EBITDA Q2Q % growth | -9.914M 27.84% | -9.177M 33.62% | -9.05M 6.90% | -5.952M 11.33% | -9.404M 5.14% | -7.14M 22.19% | -5.202M 42.52% | -3.06M 48.59% |
| EBIT Q2Q % growth | -16.391M -2.22% | -16.729M 9.53% | -15.345M 8.73% | -3.818M 76.49% | -16.443M -0.32% | -14.295M 14.55% | -12.233M 20.28% | -10.189M -166.84% |
All data in USD
10 analysts have analysed SOPH and the average price target is 7.48 USD. This implies a price increase of 62.26% is expected in the next year compared to the current price of 4.61.
SOPHIA GENETICS SA (SOPH) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of SOPHIA GENETICS SA (SOPH) is -0.25 USD and the consensus revenue estimate is 20.81M USD.
The number of analysts covering SOPHIA GENETICS SA (SOPH) is 10.